Research Radboud technology centers Radboud Biobank News Financial regulation for sub-biobanks
15 September 2020

Sub-biobanks are not required to pay up-front for the processing and storage of biomaterials because the Radboud Biobank aims to facilitate all researchers in building up a valuable collection. These costs are covered later by the issuance fee. The effectiveness of this pre-financing agreement however is dependent on adherence to the demands regarding delivery and processing according to the Radboud Biobank standard operating procedures. Standardization leads to high quality samples, increases the usability of the samples and the chance of pooling collections. Furthermore,  it ensures that the costs for processing and storage are returned to the Radboud Biobank. For this reason, the Radboud Biobank has implemented the following financial regulation for sub-biobanks that do not deliver the biomaterials according to Radboud Biobank standards.

Should the delivery of biomaterial for processing and storage by the Radboud Biobank deviate from the Radboud Biobank standard by 5% or more of the inclusions in a sub-biobank, the sub-biobank will be required to pay the processing costs of the biomaterial up-front.

The following terms and conditions apply:

  • At least 40 samples have been included in the sub-biobank
  • On delivery ≥5% of the samples deviate from the Radboud Biobank standard
  • The sub-biobank is responsible for the deviation in delivery
  • The sub-biobank is warned and has 4 months to improve the delivery of the biomaterial
  • The Radboud Biobank actively assists with finding a solution
  • If the delivery does not improve after 4 months the Radboud Biobank invoices the processing costs of the biomaterial to the sub-biobank
  • It concerns samples for which the Radboud Biobank would normally cover the costs of processing and storage up-front
  • The Radboud Biobank will continue to cover the storage costs until issuance.
  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud Biobank

Related news items


Dutch-Nordic Alliance for Precision Cancer Medicine launched

26 November 2021

The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.

read more

New Automated PBMC isolation method introduced in LMI.

21 September 2021

The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.

read more

Health-RI, geared up to accelerate

21 September 2021

The Dutch cabinet has selected Health-RI's National Growth Fund proposal for a national health data infrastructure. On 5 October, the kick-off will take place during a live meeting in Jaarbeurs Media Plaza in Utrecht.

read more

SUNRISE-CRC sub-biobank

21 September 2021

The main purpose of SUNRISE-CRC is to determine whether treatment with a high dose of sunitinib provides a better chance of survival and slows the progression of (colo)rectal cancer (CRC) more than standard treatment with TAS-102.

read more

PRECISE sub-biobank

21 September 2021

The aim of the PRECISE biobank is to develop the first, smart multi-modal liquid biopsy test service for the prediction of immune checkpoint inhibitor response in urothelial cancer (UC) patients – the PRECISE IVD.

read more

Lysine Metabolism sub-biobank

21 September 2021

Hereditary metabolic disorders form a large group of more than 1,400 rare disorders in which an error in the DNA causes abnormalities in the process in which proteins, fats and carbohydrates are converted into smaller building materials and energy.

read more